Again, suspecting CADM, we additionally conducted tests for anti-small ubiquitin-like modifier-1 activating enzyme (SAE) and anti-NXP2 antibodies in the laboratory by immunoprecipitation followed by western blot analysis, which revealed positivity for the anti-NXP2 antibody (Fig. 1E). The gene discussed is MORC3; the disease is clinically amyopathic dermatomyositis.